NRC Form 374A (8-82) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 10-01169-01

Docket or Reference number: 030-01350

Amendment No. 54

V. A. Medical Center
1670 Clairmont Road
Decatur, Georgia 30033

In accordance with letters dated January 7 and January 28, 1985, License Number 10-01169-01 is amended as follows:

To amend Items 6, 7, 8 and 9 to read:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2.5 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.

ML20
'11

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 10-01169-01

Docket or Reference number: 030-01350

Amendment No. 54

(continued)

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
E. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	E. Any	E. 3 millicuries of each byproduct material authorized in Subitem 6.E.
F. Xenon 133	F. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	F. 200 millicuries
G. Iodine 131 or 125	G. Any	G. 100 millicuries
H. Carbon 14	H. Any	H. 2 millicuries
I. Hydrogen 3	I. Any	I. 250 millicuries
J. Phosphorus 32	J. Any	J. 100 millicuries
K. Chromium 51	K. Any	K. 500 microcuries
L. Sulfur 35	L. Any	L. 100 millicuries
M. Hydrogen 3	M. Labelled Steroid Hormone	M. 5 millicuries

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 10-01169-01

Docket or Reference number: 030-01350

Amendment No. 54

(cont'd)

N.	Sulfur 35	N.	Labelled Steroid Hormone	N.	100 microcuries
O.	Carbon 14	O.	Labelled Steroid Hormone	O.	5 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

E. In-vitro studies.

F. Blood flow and pulmonary function studies.

G. through L. In vitro research and animal studies.

M., N., and O. To study humans as approved by a Food and Drug Administration Approved Radioactive Drug Research Committee.

Condition 12 is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Yavuz A. Tarcan, M.D.	Groups I, II, III, IV and V In vitro studies Licensed material for in vitro research studies and animal studies Xenon 133

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 10-01169-01

Docket or Reference number: 030-01350

Amendment No. 54

12. (Continued)

William A. Fajman, M.D.	Groups I, II, III, IV and V In vitro studies Licensed material for in vitro research studies and animal studies Xenon 133
W. Lee Hand, M.D.	Licensed material for in vitro research studies and animal studies
Zafar H. Israili, Ph.D.	Licensed material for in vitro research studies and animal research
James D. Johnson, Ph.D.	Licensed material for in vitro research studies and animal studies
John R. K. Preedy, M.D.	Carbon 14, Hydrogen 3, and Technetium 99m, for in vitro research studies and animal studies Subitems M., N., and O.
Leo G. Morin, Ph.D.	Licensed material for in vitro research studies and animal studies
Delwood C. Collins, Ph.D.	Licensed material for in vitro research studies and animal studies
Sam Dixon Graham, Jr., M.D.	Chromium 51 for in vitro research studies and animal studies
David H. Lawson, M.D.	Hydrogen 3 and Iodine 125 for in vitro research studies and animal studies
Ann Richmond, Ph.D.	Hydrogen 3 and Iodine 125 for in vitro research studies and animal studies
Hans-Jurgen Ristow, M.D.	Carbon 14, Hydrogen 3, Sulfur 35, and Phosphorus 32 for in vitro research studies and animal studies
Roy A. E. Bakay, M.D.	Hydrogen 3 for in vitro research studies and animal studies

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 10-01169-01

Docket or Reference number: 030-01350

Amendment No. 54

12. (continued)

Ralph B. Perkerson, J., M.D.	Groups I, II and III Xenon 133
Raymond F. Schinazi, Ph.D.	Carbon 14 and Iodine 125 for In vitro studies
Garth E. Austin, M.D., Ph.D.	Hydrogen 3 and Phosphorus 32 for in vitro studies
Rajender K. Chawla, Ph.D.	Iodine 125 for in vitro studies

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAY 16 1985

By PAUL R. GUINN

Region II, Nuclear Materials
Safety Section
101 Marietta Street, Suite 2900
Atlanta, GA 30323